Does anyone wonder what happens if there is a leronlimab only arm in the animal study and if these animals do as well or better than the animals in the keytruda/leronlimab arm. How would Merck present such an outcome to the world regarding its most valuable drug if that were to happen. This ties to ohm saying that leronlimab also inhibits PD-1, and Keytruda has serious side effects while leronlimab has none.

Would a leonlimab only arm not be permitted so as not to risk it?